What is Patent Licensing?
Exclusive, non-exclusive, and cross-licenses; running royalties and lump sums; and the clauses that decide whether a license is worth what was paid for it.
Definition
Patent licensing is a contract in which a patent owner (the licensor) grants another party (the licensee) permission to make, use, sell, or import the patented invention, usually in exchange for royalties, a lump sum, or reciprocal rights, without transferring ownership of the patent. Licenses can be limited by field of use, territory, time, and exclusivity.
Key Facts
- Ownership stays with the licensor; only an assignment transfers title
- Exclusive license: Only the licensee may practice the patent, sometimes excluding even the owner; exclusive licensees usually gain standing to sue
- Non-exclusive license: The owner may license others as well; the most common form
- Consideration: Running royalties, lump sums, minimums, milestones, equity, cross-licenses, or a covenant not to sue
- Royalty base and rate: The two numbers that matter; a low rate on total product revenue can exceed a high rate on the component
- Standard-essential patents must be licensed on FRAND terms to anyone implementing the standard
Types of Licenses
- Exclusive: One licensee, often by field or territory. Common in pharmaceuticals and university technology transfer.
- Sole: One licensee plus the owner.
- Non-exclusive: Any number of licensees. Typical for standard-essential patents, software, and settlement licenses.
- Cross-license: Two companies license portfolios to each other, often with a balancing payment; the norm among large technology companies.
- Portfolio license: Covers all of the licensor's patents in a field, which avoids charting each one and survives the invalidation of any single patent.
- Patent pool: Multiple owners license a bundle through one administrator, common for video codecs and wireless standards.
Royalty Structures
- Running royalty: A percentage of net sales or a per-unit amount, paid periodically with audit rights
- Lump sum: One payment for a defined scope and term, which shifts volume risk to the licensor
- Hybrid: An upfront payment plus running royalties, often with annual minimums
- Milestones: Payments on regulatory or commercial events, standard in life sciences
Reasonable royalty in litigation is measured by the same considerations, framed as a hypothetical negotiation at the time infringement began.
Terms That Decide Value
- Scope: Which patents, which family members, which products, which countries, and whether improvements and continuations are included
- Sublicensing and have-made rights
- Term and termination: Whether the license ends at patent expiration, on breach, or on change of control
- Most-favored-licensee clauses that ratchet rates down if someone else gets a better deal
- Validity challenges: Since MedImmune, a licensee can challenge validity without breaching; the contract may set consequences
- Marking and audit obligations
Licensing as a Program
Outbound licensing starts with knowing which patents read on which products in the market. That coverage evidence, in the form of claim charts or evidence-of-use charts, is what turns a portfolio into a revenue conversation. ArcPrime's licensing intelligence builds that map across a portfolio and ranks targets, and the licensing teams page describes the workflow end to end.
Frequently Asked Questions
Don't see the answer you're looking for?
Feel free to reach out to us for more info.
What is the difference between an exclusive and a non-exclusive license?
An exclusive license grants the rights to one licensee and bars the owner from licensing others in the same scope, and often from practicing the patent itself. A non-exclusive license allows the owner to grant the same rights to any number of parties. Exclusive licensees generally have standing to sue infringers; non-exclusive licensees do not.
What is a typical patent royalty rate?
It varies widely by industry and by how the royalty base is defined. Rates on the order of 1% to 5% of net sales are common for individual patents in many industries, with higher rates for pharmaceuticals and for exclusive licenses. The rate means little without knowing whether it applies to a component or an end product.
What is a cross-license?
An agreement in which two companies license patents to each other, usually portfolio-wide within a field, with a balancing payment if one portfolio is worth more. Cross-licenses are how large technology companies avoid mutual litigation and are a major reason to maintain a portfolio of comparable strength to competitors.
Can a licensee challenge the validity of the licensed patent?
Yes. Since MedImmune v. Genentech (2007), a licensee in good standing can challenge validity in court without first breaching the license. License agreements often address this with provisions that raise royalties or allow termination if the licensee brings a challenge.
What is the difference between a license and an assignment?
A license grants permission to practice the patent while the owner keeps title. An assignment transfers ownership. An exclusive license that transfers all substantial rights can be treated as an assignment for standing purposes.
Power Every Patent Decision
With One Platform
See how ArcPrime connects your portfolio, workflows, and business context to help your team make better decisions across the patent lifecycle.